Dextera Surgical Inc (NASDAQ:DXTR)

Will Dextera Surgical Inc (NASDAQ:DXTR) Ever Fly High Again?

Dextera Surgical Inc (NASDAQ:DXTR)

In 2011, shares of Dextera Surgical Inc (NASDAQ:DXTR) were trading above $50. Today the stock is trading below $0.20 as investors await the company’s Q1 2018 earnings announcement. The announcement will take place on Thursday, November 9, 2017, after the markets close. Analysts are expecting a loss of (-$0.06) per share.

NASDAQ:DXTR

DXTR stock last traded above the $1 level in May of 2017. This is not only a psychologically important level, but it also has a regulatory aspect to it. Section 5550(a)(2) of the Nasdaq’s Equity Rules guide states: “(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share.” Frequently companies that in violation of the “$1 Bid” NASDAQ rule complete a reverse stock split to maintain compliance. So far, there has been no news on such an eventuality from Dextera.

Dextera Surgical Inc (NASDAQ:DXTR) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted, or robotic-assisted surgical procedures annually. Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System.

DXTR Stock

Despite the multi-year downtrend and the recent EPS losses, two analysts rate DXTR stock as a “Strong Buy” while one rates DXTR stock as a “Hold”. Their consensus, one-year price target is $0.70. Earnings were projected to be -29% for 2017 but are projected at +16% for next year.

DXTR shareholders have had a rough 2017 so far. Year-to-date, DXTR shares are down over 80% and for the year shares are down over 88%.

EPS for DXTR stock has been negative since 2012 but improved each year until 2016, then a loss of (-$2.33) was posted for 2017. Sales have been rather consistent. In 2013 sales were posted at $3.5 million and that number did not substantially change over the next four years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Will Earnings Announcement Push Endocyte, Inc. (NASDAQ:ECYT) Over the Top?

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT), headquartered in West Lafayette, Indiana, will be announcing their Q3 20187 earnings after the close of the market on Monday, November 6, 2017. ACYT shares traded at less than half their monthly average volume on Friday as traders sat on the sidelines in anticipation of the news.

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT), is a biopharmaceutical company that develops therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create therapies for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.

ECYT Stock Review

At the beginning of October, ECYT stock jumped over 150% after the company announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. ABX GmbH is a German developer and manufacturer of chemicals for the nuclear medicine industry. The day after the announcement, ECYT stock hit a new 52-week high of $6.55 – well above their 52-week low of $1.17, which had been established less than 60 days earlier.

Since establishing that 52-week high, ECYT shares have retreated. The low for October was $4.14 and, three times since then, shares traded over $5, but then retreated below that psychologically important level as sellers stepped in.

Year-to-date ECYT shares are up over 96% but are down over the past month by 12%. Three firms follow Endocyte, Inc. (NASDAQ:ECYT). Two rate ECYT shares as a “Strong Buy”, while one rates the shares a “Hold”.

The last four quarterly earnings announcements from Endocyte, Inc. (NASDAQ:ECYT) have either met or beat analyst expectations. For Q3, 2017 analysts are forecasting a per share loss between (-$0.25) and (-$0.30).

Financial ratios for Endocyte, Inc. (NASDAQ:ECYT) appear very healthy. The biotech firm has a cash per share figure of $2.96. Published reports put their current ratio at a robust 22.8. A company’s current ratio is a comparison of current assets to current liabilities. It is calculated by dividing the company’s current assets by its current liabilities. Potential creditors use the current ratio to measure a company’s liquidity or ability to pay off short-term debts.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ECYT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

BioScrip Inc (NASDAQ:BIOS) Weathering Adversity

BioScrip Inc (NASDAQ:BIOS)

On Friday, BioScrip Inc (NASDAQ:BIOS) stock rebounded 8% – the day after the biotech’s shares dropped over 20% following a disappointing earnings announcement. On Thursday BIOS shares gapped down then sold off further in response to an earnings announcement of a loss of (-$12.5) million, or (-$0.125) per share, million for Q3 2017. Reports suggest that analysts were expecting a small loss of (-$0.10) per share. Revenues came in at $198.7 million which was also below the $203 million that analysts were expecting.

BioScrip Inc (NASDAQ:BIOS)

BioScrip Business

Denver, CO-based BioScrip Inc (NASDAQ:BIOS) prepares, delivers, administers, and monitors pharmaceutical treatments that are administered to patients in their own homes. BioScrip, Inc. also offers its services at outpatient clinics, nursing facilities, physician’s offices, and ambulatory infusion centers. The company markets and sells its products and services through sales and marketing representatives, payor relationships, and other government programs.

Along with the earnings announcement, BioScrip Inc (NASDAQ:BIOS) provided an update to its 2017 guidance. The company stated that revenues for the full year will be between $805.0 million to $810.0 million. These figures were lowered from earlier in the year due to the disruption from the hurricanes and the UnitedHealthcare contract transition. The Company has also updated its adjusted EBITDA guidance to a range of $42.0 million to $44.0 million 2017.

Daniel E. Greenleaf, President and Chief Executive Officer, made a statement in conjunction with the earnings release “BioScrip delivered adjusted EBITDA of $13.0 million during the third quarter of 2017, while completing the UnitedHealthcare contract transition and enduring disruption from both Hurricane Harvey and Hurricane Irma, which impacted 12 of our branches…. The turnaround plan is on schedule, driven by success in our CORE initiatives which has driven much improved and sustainable profitability and cash flow. With the UnitedHealthcare contract transition complete, we look forward to Core revenue acceleration.”

BIOS Stock Performance

In August, SunTrust upgrade its rating of BIOS shares to a “Buy” which aligned with the rating assigned by LakeStreet. The third firm that covers BioScrip Inc (NASDAQ:BIOS) is Barrington Research and they rate BIOS shares as an “Outperform”.

BioScrip’s annual sales figures increased each year from 2012, when the company reported $593.4 million, to 2015, when it reported $982.2 million. Then in 2016, sales dropped off and the company posted a sales figure of $935.6 million.

Earnings have been tough to come by for the company. Per share losses increased from 2012 (-$0.22) to 2015 (-$4.56) then contracted in 2016 (-$0.46).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BIOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DURECT Corporation (NASDAQ:DRRX)

DURECT Corporation (NASDAQ:DRRX) Coming Back to Life?

DURECT Corporation (NASDAQ:DRRX)

On Friday, DRRX stock closed at $0.95, their highest valuation since the shares cratered following a disappointing Phase 3 report almost two weeks ago. Volume for the biotechnology company was heavy – almost three times the listed daily volume average.

DURECT Corporation (NASDAQ:DRRX) shares cratered over 60% on October 20, 2017 on a volume figure of over 8.6 million – DRRX stock previously had an average daily volume of just 456,000. Investors bailed on the biotechnology company after the biotechnology company announced that its drug candidate, Posimir failed to meet its primary efficacy endpoint of pain reduction in a statistical meaningful manner in the Phase 3 PERSIST study.

DRRX Q3 Financials

The biotechnology company reported $6.1 million in Q3 net income versus a net loss of $8.8 million in Q3 2016. DURECT Corporation (NASDAQ:DRRX) reported Q3 revenues of $20.7 compared to $3.7 million over the same period last year. Q3 R&D collaboration revenues were $5.6 million versus to $0.4 million in Q3 2016.

As part of their corporate update, the company informed the public that they signed a patent purchase agreement with Indivior for Durect’s RBP-7000, yielding DURECT a $12.5 million upfront payment, as well as a possible $5 million milestone payment and potential earn-out payments.

Durect – Sandoz License Agreement

DURECT Corporation (NASDAQ:DRRX) and Sandoz AG (“Sandoz”) entered into a license agreement to develop and market POSIMIR in the United States, and the agreement became effective in June 2017. DURECT retains commercialization rights in the rest of the world.  Under terms of the agreement, Sandoz made an upfront payment of $20 million, with the potential for up to an additional $43 million in milestone payments based on successful development and regulatory milestones, and up to an additional $230 million in sales-based milestones.

DURECT is responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.  DURECT Corporation (NASDAQ:DRRX)  also has certain manufacturing obligations under this agreement.

DURECT Corporation (NASDAQ:DRRX) posted a profit of ($0.16) per share in 2012. Since then, losses have been posted every year and in 2016 they posted their largest loss of (-$0.18) per share. In 2016 the company also their lowest sales figure of $14 million.

In July, 2017 Stifel issues an upgrade to DRRX shares – from a “Hold” to a “Buy”. Then, on October 20, 2017, Stifel and H.C. Wainwright downgraded DRRX stock to a “Hold” from a “Buy”. At that time, Stifel also issued a one-year price target of $0.90.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NASDAQ:IDRA

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Moves Higher

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock has apparently come under selling pressure at the end of the last five trading sessions. Even so, IDRA stock saw a 11.5% increase over the past week. Friday’s high of $1.83 was 38% higher than the 52-week low of $1.32 which was recently established on October 26, 2017.

IDRA stock had plummeted on October 26, after Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced pricing a share offering at $1.50 – the previous close for IDRA shares was $2.03. The offering was for 33,333,334 shares of its common stock with a 30-day option to for the underwriters to purchase up to an additional 5,000,000 shares of common stock.

NASDAQ:IDRA

About Idera

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s development program focuses on boosting the immune system to play a more powerful role in fighting cancer, and ultimately increase the number of people who can benefit from immunotherapy. Idera invests in research and development, and works with investigators and partners to address the unmet needs of patients who are suffering from rare, life-threatening diseases.

IDRA Stock Performance

JP Morgan, Wedbush Securities, Piper Jaffray, and Baird all follow Idera Pharmaceuticals Inc (NASDAQ:IDRA) and rate the shares as a “Strong Buy”. The listed consensus one-year price target is $5.75. Year-to-date ODRA shares are up only 16%. For the year, IDRA stock is up 19.2%.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has posted per share losses since 2012 (-$0.81) but the trend has been favorable and the loss for 2016 was just (-$0.30). Last year the company posted their first significant sales figure of $16.2 million. The downside for investors has been the annual dilution as outstanding shares have increased every year since 2012 when the number of outstanding shares was 27.64 million. But by the end of 2016, and prior to the most recent share offering, over 127.6 million shares were listed as outstanding.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc (NASDAQ:GNMK) Tumbles

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc (NASDAQ:GNMK) shares shed over 40% of their value in Friday’s trading session after the company reported a (-$15.4) million loss, or (-$0.28) per share, for Q3 2017. Those results were in line with analyst expectations but revenues, $11.6 million, were 18% lower than what the street was expecting. GNMK shares ended the day at $4.26 on heavy volume. A stock that normally trades under 400,000 shares per day traded over seven million shares by Friday’s end of trading.

GenMark Diagnostics, Inc (NASDAQ:GNMK)

Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) experienced similar price action when they released their Q2 earnings results this past summer. The market responded to those losses by selling off the stock to the tune of 15%. At the time, shares were trading around the $10 handle. Since then, shares steadily slid to $8 before they gapped down over 40% on Thursday’s earning’s announcement.

Carlsbad, CA-based GenMark Diagnostics, Inc (NASDAQ:GNMK) is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and assist healthcare providers in determining the most efficient patient treatment. GenMark’s proprietary eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a workstation and self-contained, disposable test cartridges.

GenMark Stock

A frequent characteristic of biotech shares that dramatically underperform is the continual issuance of new shares which leads to a dilution of shareholder equity. In Genmark’s case that dilution has not been a major concern. In 2014, there were 41.35 million GNM shares outstanding. That number increased to just 44.1 million by the end of 2016. Even sales are trending upwards. For 2012, the company reported $20.5 million in sales. By 2016 that number was a robust $49.3 million.

However, GenMark Diagnostics, Inc (NASDAQ:GNMK) management has been unable to translate increasing sales into shareholder profits. Per share, the company lost (-$0.84) in 2012. That figure was followed by annual per share losses of (-$0.95), (-$0.93), (-$1.00), and, for 2016, (-$1.15). Year-to-date GNMK shares are down over 65% and have lost over 55% in the last month. That share performance is reflected in the stock’s Relative Strength Index (RSI) score of 9.7. Most observers believe that an RSI below 20 is signaling an “Oversold” condition.

Many sector observers believe that the share drop will force the Board of Directors for GenMark Diagnostics, Inc (NASDAQ:GNMK) to investigate a licensing agreement, merger, or sale in an effort to generate shareholder value.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GNMK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

VIVUS, Inc. (NASDAQ:VVUS)

OHR Pharmaceutical Inc (NASDAQ:OHRP) Stock Trying to Rebound

OHR Pharmaceutical Inc (NASDAQ:OHRP)

Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) closed higher by over 12% today on a volume figure that was over five times the listed average. Despite a lack of news concerning the pharmaceutical company, traders bid the company’s shares higher throughout the day but sellers stepped in with two hours left in the trading day and started to pressure the stock whenever it got over $0.70. OHRP shares ended the day at $0.69.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

OHR Pharmaceutical, Inc. (NasdaqCM:OHRP) develops therapeutics and delivery technologies for the treatment of ocular diseases. Their pre-clinical pipeline is focused on the development of sustained release therapeutics for ocular diseases utilizing their patented microfabrication platform technology. OHR Pharmaceutical Inc (NASDAQ:OHRP) currently has several active programs evaluating molecules and approaches for the treatment of primary open angle glaucoma, steroid-induced glaucoma, ocular allergies, and retinal diseases. The U.S. Food and Drug Administration has awarded OHR’s Squalamine Fast Track Designation for the potential treatment of wet AMD.

OHRP Stock History

OHR Pharmaceutical Inc (NASDAQ:OHRP) shares hit their peak in 2014 when OHRP was trading, albeit briefly, just below $20 per share. However, shares are now struggling to stay above the $1 threshold which not only is psychologically important, but also triggers a NASDAQ compliance rule.

In 2012 the company reported a per share loss of (-$0.10). That loss expanded each year and in 2016 the per share loss was reported at (-$0.82). A lack of earnings is not unusual for a biotechnology firm that typically has a multi-year runway to revenues due to FDA approval requirements. But the company was also diluting shareholder equity during this time. In 2012 the number of outstanding shares stood at 14.24 million. That figure expanded every year and for 2016 the company listed the number of outstanding shares at 31.35 million.

Accordingly, shares have lost nearly 60% of their value year-to-date, and nearly 80% for the year. While shares are well above their 52-week low of $0.56, they are far away from their 52-week high of $3.10, and even further away from analysts’ consensus, one-year price target of $10.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHRP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS) Beats Street Expectations

Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS) stock has broken through a resistance trend line and is up a whopping 20.5% after the company reported losses that beat street expectations. reported a loss of $13.4 million in its third quarter. Concord, CA-based Cerus Corporation reported a (-$0.12) per share loss against the (-$0.15) loss analysts were expecting.

Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS) is a biomedical company that develops products to improve the safety profile of blood transfusions. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections. Cerus currently markets and sells the INTERCEPT Blood System globally.

Cerus Q3 Earnings

Operating losses from Q3 2017 were $12.4 million, compared to $14.3 million for the same period in 2016, and $46.7 million compared to $46.3 million for the nine months ended September 30, 2017 and September 30, 2016, respectively.

Net loss for Q3 2017 was $13.4 million, or (-$0.12) per diluted share, compared to a net loss of (-$14.4) million, or (-$0.14) per diluted share, for the third quarter of 2016. Net loss for the first nine months of 2017 was (-$49.1) million, or (-$0.46) per diluted share, compared to a net loss of (-$49.4) million, or (-$0.49) per diluted share, for the same period of 2016.

CERS Stock

Three investment firms follow Cerus Corporation (NASDAQ:CERS). All three assign CERS stock a rating of “Strong Buy”. The analysts’ consensus, one-year target price is $6.33.

In mid-2016, CERS shares were briefly trading over $7.00, but then started a slow, steady slide until they hit their 52-week low of $1.93 in May of 2017. Accordingly, the stock has lost about 33% year-to-date. However shares have gained over 16% during the past quarter. The recent gains have been reflected in the company’s Relative Strength Index score of 73 – a number above 70 is usually taken to signal an “overbought” condition.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Second Sight Medical Products Inc (NASDAQ:EYES),

Good News for Second Sight Medical Products Inc (NASDAQ:EYES)

Second Sight Medical Products Inc (NASDAQ:EYES)

Shares of Second Sight Medical Products Inc (NASDAQ:EYES), headquartered in Sylmar, CA, are up over 10% in late trading on the back of a ten-fold volume increase. The strong move upwards was a result of investor reaction to the consent of the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The approval allows two U.S. sites, the University of California at Los Angeles (UCLA) and Baylor College of Medicine (Baylor) in Houston, to enroll up to five total patients.

Second Sight Medical Products Inc (NASDAQ:EYES),

Second Sight Medical Products Inc (NASDAQ:EYES)’s develops, manufactures, and markets innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight’s Orion™ Visual Cortical Prosthesis is being developed to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions.

Will McGuire, President and CEO of Second Sight stated ““We remain on track toward achieving our stated goal of implanting our first Orion patient before year end, and the potential opportunity to provide useful vision to millions of blind individuals worldwide who have no other option today,”

EYES Stock Performance

Despite the science fiction nature of their product that could change the lives of millions of blind people, current financial results have been poor for shareholders. In late 2015, EYES stock was trading above $7, but a lack of profits has seen a downward trend for the shares. In February of 2017, EYES stock briefly rose near $3, but during most of the past year has had the stock below the $2 level.

EYES stock is down 55% for the year, and down 4% for the past month. There is a moderate short position on the company – over 10% of the share’s float is held as a short position.

HC Wainwright covers Second Sight Medical Products Inc (NASDAQ:EYES) and assigns EYES stock a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EYES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Continues Move Higher

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares are up 31%, to $7.36, on news of a research collaboration and license agreement with Boehringer Ingelheim to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. Under the terms of the agreement, Dicerna may receive more than $200 million in upfront, development and commercial milestone payments, and research and development reimbursement for a GalXC candidate product addressing an undisclosed NASH target. Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), based in Cambridge, MA, discovers and develops RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where there are recognized connections between the target gene and diseases.

Dicerna’s GalXC technology platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. This new approach has the potential to treat diseases by silencing previously inaccessible drug targets.

Douglas M. Fambrough, President and Chief Executive Officer of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) stated, “With strong capabilities in drug discovery, deep expertise in the cardiometabolic space, and proven commercial experience, Boehringer Ingelheim is a natural partner to speed the development of the first GalXC RNAi program targeting chronic liver disease. The collaboration combines the strong capabilities of both companies to pursue the full potential of Dicerna’s GalXC technology to bring valuable and differentiated RNAi therapies to patients with liver diseases and their healthcare teams, and reflects both the promise of the GalXC technology and the strength of its underlying intellectual property.”

DRNA Stock Performance

Five investment firms follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Four rate DRNA shares as a “Strong Buy” and one rates the shares as a “Hold”.

In 2016, DRNA shareholders saw a per share loss of (-$2.87) on total sales of just $300,000. Despite those numbers, shareholders have seen a year-to-date gain of over 95%. Today’s price action (currently at $7.36) eclipses the previous 52-week high of $6.75 and also tops analyst’s consensus one-year price target of $5.75.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRNA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.